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Medicinal plants have been a main source of therapeutic agents from ancient time to cure diseases. Ter-
minalia arjuna (Roxb.) Wight & Arn. (T. arjuna) is one of the most accepted and beneﬁcial medicinal plants
in indigenous system of medicine for the treatment of various critical diseases. This comprehensive review
provides various aspects of its ethnomedical, phytochemical, pharmacognostical, pharmacological and
clinical signiﬁcance to different diseases particularly in cardiovascular conditions. This plant has a good
safety outline when used in combination with other conventional drugs. This review highlights various
medicinal properties of T. arjuna through different studies such as antioxidant, hypotensive, anti-
atherogenic, anti-inﬂammatory, anti-carcinogenic, anti-mutagenic and gastro-productive effect.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Medicinal plants play an essential role in health care and are the
major rawmaterials for both traditional and conventional medicine
preparations; still most of the people choose herbal medicines than
conventional medicines.1 They expanded attention due to their
effectiveness, lack of current medical alternatives, increasing cost of
modern medicines and cultural preferences.2,3 Ethnobotanical
studies are most important to expose the ancient times and current
culture about plants in the world and reserving original knowledge
of medicinal plants. The quantitative ethnobotanical studies were
used to identify the plant uses as food,4 human health care medi-
cines,5 veterinary medicine6 and economically important.7
Around the world, the traditional knowledge system has
expanded chief importance in perspective with protection, sus-
tainable growth and search for new utilization patterns of plant
resources. Traditional medicine system includes the knowledge,
skills and practices based on the presumptions, beliefs and expe-
riences of folk communities to protect their health problems.
Traditional herbal medicines are considered to be of huge impor-
tance among different rural or native communities in manyopi).
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).developing countries.8 According to WHO, almost 80% of the
world's population depending on traditional medicine and in India
60% of the people in rural areas use herbal medicines.1 During the
last few years, use of herbal supplements increased from 2.5% to
12%.9 In recent years, there has also been an increasing demand for
nanoparticles derived from medicinal plants like Terminalia family
due to their applications in various ﬁelds of research like medicine,
catalysis, energy and materials.10e12
In the earliest India, medicinal plants were used to prevent
different critical diseases and they would be the best source to
obtain a variety of drugs. The Indian traditional medicine is based
on various systems such as Ayurveda, Siddha, Unanai, etc. In recent
years there has been an increasing awareness about the importance
of medicinal plants. Herbal drugs are easily accessible, secure, less
pricey, efﬁcient and have very rare side effects. The evaluation of
new drugs, especially the phytochemical obtained materials has
opened a vast area for research and helpful in making a transition
from traditional to modern medicine in India. Medicinal plants
contain some organic compounds which provide deﬁnite physio-
logical action on the human body and these bioactive substances
include tannins, alkaloids, carbohydrates, terpenoids, steroids, ﬂa-
vonoids, and phenols.13
Even though numerous medicinal plants have been explained
in the Indian customary therapeutic system for treatment of
several diseases, very few plant products are nowadays utilized in
the modern medical system to treat most of the diseases,rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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cough, excessive perspiration, asthma, tumor, inﬂammation and
skin disorders. Among the plants, one of the medicinal plants
indigenous to India is Terminalia arjuna (Roxb.) Wight and Arn.,
(T. arjuna) commonly known as ‘Arjuna’, which has been used as
a cardiotonic in heart failure, ischemic, cardiomyopathy, athero-
sclerosis, myocardium necrosis and has been used for the treat-
ment of different human diseases like blood diseases, anemia,
venereal and viral disease; and to continue excellent healthiness.
It is used in the treatment of fractures, ulcers, hepatic and showed
hypocholesterolemic, antibacterial, antimicrobial, antitumoral,
antioxidant, antiallergic and antifeedant, antifertility and anti-
HIV activities.14e16 T. arjuna is reported that to possess strong
hydrolipidemic properties. It is trusted that the saponin glyco-
sides in T. arjuna may be responsible for its inotropic effects,
while the ﬂavonoids/phenolics may supply antioxidant activity as
well as vascular ampliﬁcation activity, in this manner authenti-
cating the multiple activities of this plant for its cardio-protective
function.17e19 The aim of this review is to summarize the infor-
mation and knowledge about the T. arjuna and updating available
research data on the aspects of botany, ethnopharmacology,
phytochemistry and clinical studies.2. Methods
Systematic literature searches were carried out and the available
information on various plants traditionally used for cardiovascular
disorders was collected via electronic search (using Pubmed, Sci-
Finder, Scopus, Scirus, ScienceDirect, Google Scholar and Web of
Science) and a library search for articles published in peer-reviewed
journals and also locally available books.3. Occurrences, botanical description and
ethnopharmacology
T. arjuna is an ayurvedic plant with important medicinal value. It
is commonly known as Arjuna, Indradru, Partha and Veeravriksha20
which is belongs to Combretaceae family comprising of nearly 200
species distributed around theworld. Nearly 24 species of Terminalia
have been reported from various parts of India, some selected spe-
cies are T. arjuna, Terminalia bellirica, Terminalia bialata, Terminalia
catappa, Terminalia elliptica, Terminalia porphyrocarpa, Terminalia
mantaly etc. In India, T. arjuna is about 60e80 feet in height,
buttressed trunk and horizontally spreading crown and drooping
branches distributed in India, Burma, Mauritius and Sri Lanka.19,21,22
T. arjuna is distributed throughout sub Indo-Himalayan tracts of
Uttar Pradesh, Punjab, Deccan, South Bihar, Orissa, West Bengal and
Madhya Pradesh mainly along riverside, rivulets and ponds. It is
known by its various vernacular names, the most commonly used
ones are Arjuna (Common Name), Arjun (Hindi), Marudhu (Tamil
and Malayalam), Tella Maddi (Telugu), Arjhan (Bengali), Sadaru
(Marathi), Sadado (Gujarati), Neer matti (Kannada) and some
traditional formulations prescribe in the name of Arjunarishta and
Arjunaghrita.
Leaves of T. arjuna are simple, often crenulations, borne sub-
opposite, shortly acute or obtuse at the apex, coriaceous and
oblong or elliptic. Their upper face is pale or dark green and the
lower face is pale brown. The tree bears white sessile bisexual
ﬂowers in short auxiliary spikes or in a terminal panicle arrange-
ment. Fruits of T. arjuna are drupe, ovoid, ﬁbrous-woody and
smooth-skinned with ﬁve hard wings or angles which are oblique
and curved upwards. Stem bark is simple, smooth and pinkish-gray
in color in external view. An internal view, the bark is soft and
reddish in color.234. Phytochemistry
The major constituents of T. arjuna in stem bark, root bark,
fruits, leaves and seeds are well characterized (Table 1). The pre-
liminary phytochemical analysis of existing compounds in
T. arjunawas carried out according to various standard protocols as
mentioned by Harbone54 in Table 2. As bark was considered to be
the most important constituent from the medicinal point of view,
initially reported that the bark had 34% ash content consisting
entirely of pure calcium carbonate. Aqueous extract of T. arjuna is
reported to have 23% calcium salts and 16% tannins. Organic ex-
tracts of T. arjuna bark were also prepared using the sequential
methods with a number of organic solvents such as hexane, ben-
zene, chloroform, acetone, dichloromethane, ethyl acetate,
butanol, ethanol, methanol and ether, etc., to extract various
phytochemical constituents. The chemical structures of available
compounds were conﬁrmed by various advanced techniques like
HPLC, UPLC, LC-ESI-MS/MS analysis.26,27,55,56 Polyphenols, ﬂavo-
noids, tannins, triterpenoids, saponins, sterols and minerals are
the major constituents of T. arjuna. Such amino acids like trypto-
phan, tyrosine, histidine and cysteine are also the main
ingredients in T. arjuna.24,29,31,574.1. Terpenoids, ursane triterpenoids and glycosides
At ﬁrst an oleanane triterpenoid named, arjunin, and a
lactone, arjunetin were isolated from the benzene and ethanolic
extracts of its bark respectively (Fig. 1). Honda et al25,32 initially
conﬁrmed that the presence of arjunic acid and arjungenin and
latterly reported that two more glucosides namely arjunglucoside
I and II (Fig. 1) in the stem bark of T. arjuna. Anjaneyulu and
Prasad48,49 conﬁrmed that the presence of arjunoside III and IV,
terminic acid, and a triterpene carboxylic acid by ethyl acetate
extraction of roots of T. arjuna (Fig. 1). Hexane extraction of stem
of T. arjuna authenticated that the presence of terminic acid and
b-sitosterol.28 Ali et al36 has isolated another oleanane type tri-
terpane, terminoside A from the acetone fraction of the ethanolic
extract of T. arjuna's stem bark. The structure of this new com-
pound was established as olean-1a,3b,22b-triol-12-en-28-oic
acid-3b-D-glucopyranoside. It was exhibited that terminoside A
inhibits nitric oxide production and decreases inducible nitric
oxide synthase levels in lipopolysaccharide stimulate macro-
phages.35,36 Five ursane type triterpene glucosyl ester including
new one, 2a, 3b-dihydroyurs-12,18-dien-28-oic acid 28-O-b-D-
glucopyranosyl ester, and four known ursane triterpene glycosyl
esters namely, 2a, 3b, 23-trihydroxyurs-12,18-dien-28-oic acid
28-O-b-D-glucopyranosyl ester, quadranosie VIII, kajiichigoside
and 2a, 3b, 23-trihydroxyurs-12, 19-dien-28-oic acid 28-O-b-D-
glucopyranosyl ester were isolated from bark of T. arjuna
(Fig. 2).30 3-O-b-D-glucopyranosyl-2a, 3b, 19a-trihydroxyolean-
12-en-28-oic acid, 28-O-b-D-glucopyranoside and 2a, 19a-dihy-
droxy-3-oxo-olean-12-en28-oic acid 28-O-b-D-gluco-pyranoside
are isolated from bark of T. arjuna by Choubey and Srivastava50
and Upadhyay et al51 through spectrochemical analysis. Patnaik
et al38 using chromatography technique isolated a triterpenoid
glycoside from the bark of T. arjuna and identiﬁed it is an olean-
3b, 22b-diol-12-en-28 b-D-glucopyranoside-oic acid. Alam et al39
were isolated two more glycosides namely Termiarjunoside I
(olean-1a,3b,9a,22a-tetraol-12-en-28-oicacid-3b-D-glucopyrano-
side) and Termiarjunoside II (Olean-3a,5a, 25-triol-12-en-23,28-
dioicacid-3b-D-glucophyranoside) from the ethanolic extract
of TA bark. Arjunglucoside IV and V, Arjunasides A-E were
isolated from the ethanolic extract of the stem bark of T. arjuna
by Wang et al.30,58
Table 1
Phytochemical constituents of various parts of Terminalia arjuna (Roxb.) Wight and Arn.
Part used Major chemical constituents References
Stem bark Triterpenoids
Arjunin Row et al24
Arjunic acid
Arjungenin Honda et al25
Singh et al26,27
Terminic acid Anjaneyulu and Prasad28
Terminoltin Singh et al29
Arjunolic acid Singh et al26,27
Ursane triterpenoids
2a,3b-dihydroyurs-12,18-oic acid 28-O-b-D-glucopyranosyl ester
2a,3b,23-trihydroxyurs-12,18-dien-28-oic acid 28-O-b-glucopyranosyl ester
Qudranoside VIII
Kajiichigoside F1
2a,3b,23-trihydroxyurs-23-trihydroxyurs-12,19-dien-28-oic acid 28-O-b-D-glucopyranosyl ester
Wang et al30
Glycosides
Arjunetin Row et al24,31
Singh et al26,27
Arjunoside I, II Honda et al25,32
Arjunolone Sharma et al33
Arjunolitin Tripathi et al34
Arjunaphthanoloside Ali et al35,36
Arjunglucoside IV and V, Arjunasides A-E Wang et al34,37
Olean-3b, 22b-diol-12-en-28 b-D-glucopyranosie-oic acid Patnaik et al38
Terminarjunoside I and II Alam et al39
Terminoside A Ahmad et al40
Termionic acid
Flavonoids and phenolics
Arjunone Sharma et al33
Luteolin Pettit et al41
Baicalein Anonymous42
Ethyl gallate
Gallic acid
Kempferol
Oligomeric proanthocyanidins
Pelargonidin
Quercetin
(þ)-catechin, (þ)-gallocatechin and ()-epigallocatechin Saha and Pawar43
Gallic acid, ellagic acid and its derivatives such as 3-O-methyl-ellagic acid 4-O-b-D-xylopyranoside,
3-O-methyl ellagic acid 3-O-rhamnoside
3-O-methyl ellagic acid 40-O-a-L-rhamnophranoside
()-epicatechin
Wang et al30
Tannins
Pyrocatechols Takahashi et al44
Punicallin Lin et al45
Castalagin Kuo et al46
Casuariin
Casuarinin
Punicalagin
Terchebulin
Terﬂavin C
Minerals and trace elements
Calcium, magnesium, aluminum, zinc, copper, silica Dwivedi and Udupa47
Other compounds
b-Sitosterol Anjaneyulu and Prasad28
Roots Triterpenoids
Arjunoside I-IV Anjaneyulu and Prasad48,49
Arjunolic acid Anjaneyulu and Prasad28
Oleanolic acid
Terminic acid
2a,19a-Dihydroxy-3Oxo-Olean-12-En28-Olic acid 28-O-b-D-glucopyranoside Choubey and Srivastava50
Arjunic acid Singh et al26,27
Glycosides
Arjunetosie (3-O-b-D-glucopyranosyl-2a, 3b, 19a-trihydroxyolean-12-en-28-oic acid
28-O-b-D-glucopyranoside)
Upadhyay et al51
Fruits Triterpenoids and ﬂavonoids
Arjunic acid, Arjunone, Arachidic stearate, Cerasidin, Ellagic acid, Fridelin, Gallic acid, Hentriacontane,
Methyl oleaolate, Myristyl oleate, b-Sitisterol
Rastogi and Mehrotra52
Leaves and seeds Flavonoids and glycosides
Luteolin, 14,16-dianhydrogitoxigenin 3-b-D-xylopyranosyl-(1 > 2)-O-b-D-galactopyranoside Pettit et al41
Yadava and Rathore53
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Table 2
Preliminary tests for phytochemical analysis of the Terminalia arjuna (Roxb.) Wight
and Arn. extract.
Phytoconstituents Test
Alkaloides Dragendroff's test
Carbohydrates Molisch's test
Flavonoids Lead acetate test
Glycosides KellereKilliant test
Lactones Legal's test
Phenolic compounds and tannins 5% FeCl3 test
Proteins Ninhydrin test
Phytosterols Salkowski's test
Saponins Foam test
Triterpenoids LiebermanneBurchard's test
Fig. 1. Structure of important terpenoids and g
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Bark of T. arjuna contains a very high level of ﬂavonoids, namely
arjunolone, ﬂavones, luteolin, baicaleiin, quercetin, kempferol, and
pelargonidin evaluated with other medicinal plants particularly
having favorable effects on cardiovascular diseases. The compound
luteolin has been isolated from the butanolic fraction of T. arjuna
and it has been found to be antimutagenic and antibacterial ac-
tivity. It inhibited gram negative pathogen growth with a minimum
inhibitory concentration of 12.5 mg/disc. Aqueous extract of
T. arjuna contains 70% polyphenols having a molecular weight
greater than 3.5 kDa and they are conﬁrmed by the HPLC and LC-
MS. The aqueous extract contains ﬂavon-3-ols, such as (þ)-cate-
chin, (þ)-gallocatechin and ()-epigallocatechin; gallic acid, ellagic
acid and its derivatives such as 3-O-methyl ellagic acid 4-O-b-D-
xylopyranoside and 3-O-methyl ellagic acid 3-O-rhamnosidelycosides isolated from Terminalia arjuna.
Fig. 2. Structure of ursane triterpenoids isolated from Terminalia arjuna.
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LDL oxidation, endothelial activation and platelet aggregation.59e62
Due to the presence of free radical scavenging action of the various
phenolic contents in T. arjuna, it acts as strong anti-proliferative and
anti-oxidant agent.63 There is an inversely relationship between the
high intake of dietary ﬂavonoids and the risk of coronary artery
disease (CAD), so possible account for intake of high ﬂavonoids
content TA is beneﬁcial effects in CAD.
4.3. Tannins
Tannins are known to enhance the synthesis of nitric oxide and
relax vascular segments pre-contracted with norepinephrine. In
addition to a ﬂavonoids variety of tannins have been isolated from
the bark of T. arjuna. Around ﬁfteen types of tannins and theirrelated compounds were isolated from the bark of T. arjuna and
their structures were elucidated with the help of spectral analysis.
Hydrolyzable tannins are castalagin, casuariin, casuarinin, punica-
lagin, pyrocatechols, punicallin, terchebulin and terﬂavin C were
isolated from the bark of T. arjuna.45 Tannins are considered to have
wound healing, astringent, hypotensive, antioxidant and antimi-
crobial effects.64,65
4.4. Minerals and amino acids
The bark of T. arjuna contains large amount of various minerals
and trace elements such as magnesium (4000 mg/g), calcium
(3133 mg/g), zinc (119 mg/g) and copper (19 mg/g).47 It contains some
amino acids such as tryptophan, tyrosine, histidine and
cysteine.26,27,57
Fig. 3. Structure of important ﬂavonoids isolated from Terminalia arjuna.
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T. arjuna is a tree having an widespread medicinal potential in
most of the diseases particularly cardiovascular disorders. Scientiﬁc
investigations of T. arjuna extensively reported and discussed
through various preclinical and clinical studies (Tables 3 and 4).
5.1. Pharmacological studies
Cardioprotective potential of T. arjuna stem bark on the molec-
ular basis was evaluated by Kokkiripati et al,56 using cell cultures of
human monocytic (THP-1) and human aortic endothelial cells
(HAECs). Inhibitory effect of alcoholic (TAAE) and aqueous (TAWE)
extracts of T. arjuna stem bark was assessed on human 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase, lipoprotein
lipase (LpL) and lipid peroxidation in rat (Wistar) liver and heart
homogenates. TAAE and TAWE inhibited the lipid peroxidation and
HMG-CoA reductase. Both the extracts attenuated H2O2 mediatedROS generation in THP-1 cells by promoting catalase (CAT), gluta-
thione peroxidase (GPx) activities, and by sustaining cellular
reducing power. TAAE was highly effective in satisfying proin-
ﬂammatory gene transcripts in THP-1 cells and HAECs, whereas the
response to TAWE depended on the type of transcript and cell type.
Both extracts decreased the levels of typical inﬂammatory marker
proteins, viz. LPS induced tumor necrosis factor (TNF)-a secreted by
THP-1 cells and TNF-a induced cell surface adhesion molecules on
HAECs, namely vascular cell adhesion molecule-1 (VCAM-1) and E-
selectin. The marked effects on cultured human monocytic and
aortic endothelial cells (HAEC) provide the biochemical and mo-
lecular basis for the therapeutic potential of T. arjuna stem bark
against cardiovascular diseases (CVD).
Triterpenoids are essentially responsible for cardiovascular
properties. Alcoholic and aqueous bark extracts of T. arjuna, arjunic
acid, arjunetin and arjungenin were evaluated for their potential to
inhibit CYP3A4, CYP2D6 and CYP2C9 enzymes in human liver mi-
crosomes by Varghese et al.66 They have demonstrated that
Table 3
Pharmacological studies on Terminalia arjuna (Roxb.) Wight and Arn.
Pharmacological
activity
Model used and study design Type of extract Observations References
Antioxidant,
antiinﬂammatory,
and
immunomodulatory
CYP3A4, CYP2D6 and CYP2C9
enzymes in human liver
microsomes
Alcoholic and aqueous extract of T. arjuna at 35 mg/ml dose
level
Alcoholic and aqueous extracts of T. arjuna showed
signiﬁcant inhibition activity of CYP3A4, CYP2D6 and
CYP2C9 enzyme.
Enzyme kinetic studies suggested that the extracts of
T. arjuna showed rapidly reversible non-competitive
inhibition of all three enzymes in human liver microsomes.
Varghese et al66
Antioxidant Human polymorphonuclear
(PMN) cells and hypochlorous
acid from human neutrophils
Methanolic extract of T. arjuna Arjungenin is the most active compound than others and
had moderate inhibitory effect on the process of respiratory
oxyburst and its IC50 value is shown 60 mg/ml.
Pawar and Bhutani67
Antioxidant Male Wistar albino rats (110
e140 g) e (6e7 weeks old)
T. arjuna was administrated orally to Wistar rat at different
doses (0.42mg/kg to 6.8mg/kg) for 6 days/week for 4 weeks
Chromic administration of butanolic fraction of alcoholic
extract of T. arjuna bark has cardioprotective potential
against Dox-induced cardiotoxicity.
Singh et al68
Antioxidant and
antimutagenic
activity
Wistar rats (200e250 g) and
Swiss albino mice (18e22 g)
Aqueous and ethanolic extraction of T. arjuna The alcoholic extract of T. arjuna (ALTA) has shown potent
antioxidant activity with EC50 of 2.491 ± 0.160,
50.110 ± 0.150 and 71.000 ± 0.025 in DPPH assay,
superoxide radical scavenging activity and lipid
peroxidation assay, respectively.
In micronucleus test, EC50 of 2.410 ± 0.140, 40.500 ± 0.390
and 63.000 ± 0.360 in percentage of micronucleus in ALTA
(100 and 200 mg/kg p.o) showed signiﬁcant reduction in
both polychromatic erythrocytes and normochromatic
erythrocytes and also shown signiﬁcant reduction in P/N
ratio.
Viswanatha et al69
Anticarcinogenic and
antimutagenic
potential
In vitro and in vivo method Aqueous extracts from 75 mg/ml to 200 mg/ml for
lymphocyte culture for in vitro experiments
Aqueous extracts from 50 mg/kg to 350 mg/kg body weight
for in vivo experiments
Used human lymphocyte culture and bone marrow cells of
albino mice (8e10 weeks old and weight ranges between
25-35 g)
The number of sister chromatid exchanges got reduced
from a higher level of 15.0 ± 1.4 per cell to 7.7 ± 0.5 per cell
with S9 mix at 48 h of treatment.
The replication index was enhanced from 1.33 to 1.55
in vitro.
In the in vivo experiments, effective reduction in clastogeny
ranging from 15.22% to 54.82% from the mutagen treated
positive control and the total frequencies in aberrant cells
got reduced from 429 due to AFB1 to 141 due to 5th
concentration of T. arjuna extracts at 32 h of exposure.
Ahmad et al70
Antioxidant, anti-
inﬂammatory and
immunomodulatory
Cell cultures of human
monocytic (THP-1) and human
aortic endothelial cells (HEACs)
T. arjuna alcoholic extract (TAAE) and T. arjuna Aqueous
extract (TAWE) from steam bark at a dose of 1e50 mg/ml
TAAE and TAWE inhibited the lipid peroxidation and
attenuated H2O2 mediated ROS generation in THP-1 cells by
promoting catalase, glutathione peroxidase activities and by
sustaining cellular reducing power.
Marked effects of T. arjuna steam bark on cultured human
monocytic and aortic endothelial cells provide the
biochemical andmolecular basis for therapeutic potential of
T. arjuna steam bark against cardiovascular diseases (CVD).
Kokkiripati et al56
Antioxidant Male albino Wistar rats (120
e150 g body weight) were
subjected to oxidative stress
associated with in vitro
ischemic reperfusion injury
(IRI)
Two doses (500 and 750 mg/kg in 2% carboxy methyl
cellulose (CMC)), 6 days per week for 12 weeks
T. arjuna augments endogenous antioxidant compounds of
rat heart and also prevents oxidative stress associated with
IRI of the heart.
Gauthaman et al71
(continued on next page)
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Table 3 (continued )
Pharmacological
activity
Model used and study design Type of extract Observations References
Antioxidant Human neutrophils isolated
from fresh, heparinized human
blood by using Histoprep and
suspended in HBSS medium
containing gelatin.
Ethanolic extraction of T. arjuna containing arjunic acid,
arjungenin, arjunetin and arjunglucoside II
Arjungenin and its glucosid racted from T. arjuna and
are exhibited a signiﬁcant fre dical scavenging activity on
the superoxide release from N cells.
Arjungenin exhibited great itor action on the
hypochlorous acid productin m human neutrophils.
Pawar and Bhutani67
Antioxidant Male Wistar albino rats,
weighing between 250 and
300 g; treated with STZ at a
dose of 65 mg/kg
Therapeutic treatment through 50% ethanolic extract of
T. arjuna at a dose of 500mg/kg and rosuvastatin (20 mg/kg)
for 30 days orally after 8 weeks of STZ treatment
T. arjuna bark extract impro cardiovascular autonomic
neuropathy in rats having u trolled diabetes through
maintaining endogenous an dant enzyme activities and
decreasing cytokine levels.
Khaliq et al72
Antioxidant Male Swiss albino mice treated
with NaF at a dose of 600 mg/L
for 1 week.
Ethanolic extract of T. arjuna at a dose of 50 mg/kg of body
weight and with vitamin C at a dose of 100 mg/kg body
weight for 1 week
Ethanolic extract of T. arjun tects murine hearts from
NaF-induced oxidative stres its antioxidant properties.
Sinha et al73
Antioxidant Wistar rats weight between
200-240 g.
Ethanolic extract of T. arjuna at a dose of 500 mg/kg for 15
days was administrated orally
Prophylactic and therapeuti atment with T. arjuna
improved cardiac functions baroreﬂex sensitivity.
It is attenuated hypertrophy ﬁbrosis of the LV. T. arjuna
signiﬁcantly reduced oxidat tress and inﬂammatory
cytokine level in CHF rats
Parveen et al74
Antioxidant Poloxamer (PX)-407 induced
hyperlipidemic albino Wistar
rats
Three fractions diethyl ether, ethyl acetate and ethanol of
T. arjuna exerted hypolipidemic and antioxidative effects at
two different doses levels (175 and 350mg/kg body weight)
Hypolipidemic and antioxid ffects of T. arjuna fractions
were noticed as ethanol > d yl ether > ethyl acetate.
Ethanolic fraction of T. arjun ssesses the potent
properties of antioxidant an polipidemic than other
fractions and has therapeuti ential for the prevention of
coronary arterial disease.
Subramaniam et al75
Antioxidant Male Wistar rats treated with
isoprenaline to produce LVH
Aqueous extract of T. arjuna bark was evaluated at 63, 125
and 250 mg/kg given orally for antiﬁbrotic and antioxidant
effects in male Wistar rats given selective b-adrenoceptor
agonist isoprenaline (5 mg/kg) for 28 days
Captopril has given orally 50 mg/kg per day, an inhibitor of
angiotensin-converting enzyme used as a standard
cardioprotective drug
Aqueous extract of T. arjuna iﬁcantly prevented
isoprenaline-induced increa oxidative stress and
decline in endogenous antio nt level and also prevented
ﬁbrosis.
Kumar et al76
Antioxidant and
antimicrobial
activity
DPPH methods and Agar well
diffusion method
Methanol extracts Methanolic extracts has gre ee radical scavenging
properties.
It contains liberal amount o onoid compounds.
It is exhibited good antimicr l activity against two gram
negative bacteria (E. coli and neumonia).
Mandal et al77
Antimicrobial activity Five bacteria namely
Staphylococcus aureus (Gram
Positive)
Acinetobacter sp., Proteus
mirabilis, Escherichia coli and
Pseudomonas aeruginosa (Gram
negative) were used
Methanol, ethanol, acetone aqueous extracts from the
leaves and bark of T. arjuna
Acetone leaf extract was fou o be best against S.
aureus.Organic extract show lmost equal inhibition of all
tested Gram negative bacter xcept P. aeruginosa.
Aqueous extract of T. arjuna k exhibited good activity
against S. aureus.
Aneja et al78
Antimicrobial activity NZW albino rabbits subjected to
15 min coronary artery ligation
followed by 60 min of
reperfusion injury
Pretreatment of bark powder of 500e750 mg/kg/day for 12
weeks before ischemic-reperfusion injury
Chronic oral administration e bark of T. arjuna in rabbit
causes augmentation of my dial endogenous
antioxidants along with ind n of HSP 72.
It is offered further protecti gainst oxidative stress
associated with myocardial emic reperfusion injury.
Gauthaman et al79
Anticarcinogenic
potential
Adult ventricular myocytes
isolated from hearts of adult
male Sprague-Dawley rats (250
e300 g)
Ethanolic and aqueous extract of T. arjuna at a dose of 0.05
e100 mg/ml
Aqueous extract of T. arjuna uced cardiotonic action via
enhancing sarcoplasmic reti r function, an unique action
minimizing the occurrence rhythmias, makes aqueous
extract of T. arjuna a promis and relatively safe
cardiotonic beneﬁcial to the lth heart and the treatment
for chronic heart diseases.
Oberoi et al80
A
.A
m
alraj,S.G
opi
/
Journal
of
Traditional
and
Com
plem
entary
M
edicine
7
(2017)
65
e
78
72e ext
e ra
PM
inhib
fro
ved
ncon
tioxi
a pro
s via
c tre
and
and
ive s
ant e
ieth
a po
d hy
c pot
sign
se in
xida
at fr
f ﬂav
obia
K p
nd t
ed a
ia e
bar
of th
ocar
uctio
on a
isch
ind
cula
of ar
ing
hea
D
N
A
d
am
ag
e
p
ro
te
ct
in
g
an
d
fr
ee
ra
d
ic
al
sc
av
en
gi
n
g
D
N
A
st
an
d
br
ea
ka
ge
as
sa
y
an
d
co
m
et
as
sa
y
an
al
ys
is
by
u
si
n
g
of
p
B
R
32
2
p
la
sm
id
an
d
ra
t
ad
re
n
al
PC
-1
2
ce
lls
Et
h
an
ol
ic
ex
tr
ac
ts
an
d
it
s
fr
ac
ti
on
s
Et
h
an
ol
ic
ex
tr
ac
ts
an
d
it
s
fr
ac
ti
on
s
of
T.
ar
ju
na
ba
rk
p
ro
te
ct
ed
H
2
O
2
in
d
u
ce
d
D
N
A
d
am
ag
e.
M
ax
im
u
m
in
h
ib
it
io
n
of
D
PP
H
,h
yd
ro
xy
l,
A
B
TS
,n
it
ri
c
ox
id
e
ra
d
ic
al
s
an
d
m
et
al
ch
el
at
io
n
w
as
ob
se
rv
ed
in
et
h
yl
ac
et
at
e
fr
ac
ti
on
.
T.
ar
ju
na
ex
tr
ac
ts
am
el
io
ra
te
va
ri
ou
s
im
p
ai
rm
en
ts
as
so
ci
at
ed
w
it
h
D
N
A
d
am
ag
e
an
d
fr
ee
ra
d
ic
al
fo
rm
at
io
n
.
Ph
an
i
K
u
m
ar
et
al
1
6
G
as
tr
o-
p
ro
d
u
ct
iv
e
ef
fe
ct
D
ic
lo
fe
n
ac
so
d
iu
m
(D
IC
)
in
d
u
ce
d
ga
st
ri
c
u
lc
er
in
ex
p
er
im
en
ta
lr
at
s
(m
al
e
al
bi
n
o
ra
ts
of
W
is
ta
r
e
(1
50
e
20
0
g
w
ei
gh
t)
M
et
h
an
ol
ic
ex
tr
ac
t
of
T.
ar
ju
na
A
si
gn
iﬁ
ca
n
tr
ed
u
ct
io
n
in
le
si
on
in
d
ex
w
as
ob
se
rv
ed
in
u
lc
er
in
d
u
ce
d
an
im
al
s
tr
ea
te
d
w
it
h
T.
ar
ju
na
(D
IC
þ
TA
)c
om
p
ar
ed
to
u
lc
er
at
ed
ra
ts
(D
IC
).
A
si
gn
iﬁ
ca
n
t
in
cr
ea
se
w
as
ob
se
rv
ed
in
p
H
,N
P-
SH
,G
SH
,
en
zy
m
at
ic
an
ti
ox
id
an
ts
,p
ro
te
in
bo
u
n
d
ca
rb
oh
yd
ra
te
co
m
p
le
xe
s,
ad
h
er
en
t
m
u
cu
s
co
n
te
n
t,
n
u
cl
ei
c
ac
id
w
it
h
a
si
gn
iﬁ
ca
n
t
d
ec
re
as
e
in
vo
lu
m
e
of
ga
st
ri
c
ju
ic
e,
fr
ee
an
d
to
ta
l
ac
id
it
y,
p
ep
si
n
co
n
ce
n
tr
at
io
n
,a
ci
d
ou
tp
u
t,
LP
O
le
ve
ls
an
d
M
PO
ac
ti
vi
ti
es
in
D
IC
þ
TA
ra
ts
co
m
p
ar
ed
to
D
IC
ra
ts
.
D
ev
ie
t
al
8
1
A. Amalraj, S. Gopi / Journal of Traditional and Complementary Medicine 7 (2017) 65e78 73alcoholic and aqueous bark extract of T. arjuna showed effective
inhibition of all three enzymes in human liver microsomes with
IC50 values less than 35 mg/ml. Enzyme kinetics studies suggested
that the extracts of T. arjuna showed rapidly reversible non-
competitive inhibition of all three enzymes in human liver micro-
somes. They suggest strongly that T. arjuna extracts signiﬁcantly
inhibit the activity of CYP3A4, CYP2D6 and CYP2C9 enzymes.
Ahmad et al70 investigated and highlighted the anticarcinogenic
and antimutagenic potential of extracts of T. arjuna. They have used
human lymphocyte culture and bonemarrow cells of albinomice as
assay system. The parameters of studied were included chromo-
somal aberrations (CA), sister chromatid exchanges (SCEs) and cell
growth kinetics (RI) both in the presence and in the absence of
exogenous metabolic activation system for in vitro experiment,
whereas total aberrant cells and the total frequencies of aberrations
were taken for in vivo study. The role of T. arjuna extracts in
reducing metaphase aberrations due to aﬂatoxin B1 (AFB1) is quite
signiﬁcant, the reduction varying from 23.49%, 42.47%, and 59.65%
down to 12.32%, 28.00%, and 36.88% respectively at the highest
dose T. arjuna for the three different durations viz., 24, 48 and 72 h.
Similarly the number of sister chromatid exchanges got reduced
from a higher level of 15.00 ± 1.40 per cell to 7.70 ± 0.50 per cell
with liver microsomal metabolic activation system mix at 48 h of
treatment. The replication index was enhanced from 1.33 to 1.55 in
the in vitro experiment. Similar trends were noticed in the in vivo
experiments that are effective reductions in clastogeny ranging
from 15.22% to 54.82% from the mutagen treated positive control
and the total frequencies in aberrant cells got reduced from 429 due
to AFB1 to 141 due to 5th concentration of T. arjuna extracts at 32 h
of exposure. Arjungenin and its glucoside are extracted from
T. arjuna and exhibited a moderate free radical scavenging activity
on the superoxide release from PMN cells. Arjungenin also
exhibited greater inhibitory action on the hypochlorous acid pro-
duction from human neutrophils.67 Viswanatha et al69 investigated
the antioxidant and antimutagenic activities of alcoholic extract of
TA bark. The alcoholic extract of the stem bark of T. arjuna (ALTA)
has shown potent antioxidant activity with EC50 in DPPH assay,
superoxide radical scavenging activity and lipid peroxidation assay.
In micronucleus test ALTA showed signiﬁcant reduction in per-
centage of micronucleus in both polychromatic erythrocytes (PCE)
and normochromatic erythrocytes (NCE) and also shown a signiﬁ-
cant reduction in P/N ratio. Singh et al68 investigated the effects of
butanolic fraction of T. arjuna bark on Doxorubicin (Dox) induced
cardiotoxicity using in vivo study with male Wistar rats and they
found that T. arjuna bark has protective effects against Dox-induced
cardiotoxicity and may have potential as a cardioprotective agent.
Dried pulverized bark of T. arjuna was administered orally to
Wistar albino rats (120e150 g) in two doses (500 and 750 mg/kg in
2% carboxy methyl cellulose (CMC)), 6 days per week for 12 weeks.
The determination of baseline changes in cardiac endogenous
antioxidant compounds [superoxide dismutase (SOD), reduced
glutathione (GSH) and catalase (CAT)] or the hearts were subjected
to oxidative stress associated with in vitro ischemic-reperfusion
injury (IRI). Signiﬁcant rise in myocardial thiobarbituric acid reac-
tive substance (TBARS) and loss of SOD, GSH and CAT occurred in
the vehicle-treated hearts subjected to in vitro IRI. Hearts of rats
were signiﬁcantly protected from oxidative stress, when subjected
to in vitro IRI. The crude bark of TA augments endogenous antiox-
idant compounds of rat heart and also prevented oxidative stress
associated with IRI of the heart.71 Vascular complications are a
leading cause of mortality and morbidity in diabetic patients.
Therapeutic potential of T. arjuna bark extract was examined in
improving myocardial function in streptozotocin (STZ) induced
diabetic rats. After 8 weeks of STZ administration, rats showed a
decline in left ventricular pressure (LVP), maximal rate of rise and
Table 4
Clinical studies on Terminalia arjuna (Roxb.) Wight and Arn.
Highlights of the study Clinical conditions Drug formulation and dosage Clinical outcome References
Idiopathic and
ischemic cause
93 patients with dilated cardiomyopathy
(DCMP) of idiopathic and ischemic cause
T. arjuna capsules (500 mg at 8 hourly) Patients with dilated cardiomyopathy with or
without heart failure and reduced left ventricular
ejection fraction due to either idiopathic or ischemic
cause receiving combined standard therapy, and
herbal medication showed signiﬁcant improvement in
systolic and diastolic functions as well as functional
capacity in comparison to those receiving only standard
therapy or only herbal medications
Bhawani et al82
Heart failure 12 patients with refractory chronic
congestive heart failure
Aqueous extract from bark of T. arjuna was
controlled 8 h at a dose of 500 mg
Adjuvant T. arjuna therapy in selected patients with
refractory congestive heart failure, mostly related to
idiopathic dilated cardiomyopathy, appeared safe and
caused long lasting improvement in symptoms and
signs of heart failure along with improvement in left
ventricular ejection phase indices with deﬁnite
improvement in quality of life
Bharani et al83
Anti-ischemic effects 40 patients with acute myocardial infarction
with ischemic mitral regurgitation
Double-blind study with 500 mg thrice daily
for 3 months along with conventional therapy
Reduction in mitral regurgitation jet area
Improvement in E/A ratio
Dwivedi et al84
Anti-ischemic effects 58 males with chronic stable angina
(NYHA class IIeIII) with evidence of
provocable ischemia
T. arjuna (500 mg 8 h), isosorbide mononitrate
(40 mg/daily) or a matching placebo for one
week each, separated by a wash-out period of
three days in a randomized, doubled blind
crossover design
Signiﬁcant decrease in the frequency of angina
and need for isosorbide dinitrate
Signiﬁcant improvement in the treadmill exercise.
The total duration of exercise increased
Bharani et al85
Hypertension 36 hypertensive patients (stage III)
with increased LV mass
Ayurvedic formulation of T. arjuna, known as
‘Arjuna Kwath’ (25 ml twice a day)
A signiﬁcant decrease in both SBP and DBP
(P < 0.001) in both the groups
LV mass index was only signiﬁcantly reduced
in the atenolol-plus-‘Arjuna Kwatha’ group
as compared to atenolol
Rao et al86
Antioxidant, lowering
effects of lipid
and lipoprotein
100 patients with stable CAD In a placebo-controlled double-blind study,
500 mg of T. arjuna along twice a day in
addition to receive the conventional treatment
A signiﬁcant decrease in hyperlipidemia as well
as in various inﬂammatory cytokines such as hsCRP,
IL-18 (P,0.001), IL-6 and TNF-a (P < 0.05) was
observed at 3 months in patients
Kapoor et al19
Antioxidant activity 30 patients with coronary artery disease 500 mg bark powder of T. arjuna combined
with conventional drugs
16% reduction in LDL cholesterol
15% decrease in cholesterol
11% decrease in triglycerides
Marginal decrease in nitrite levels
Khalil87
Antioxidant activity 105 patients with stable
coronary heart disease (CHD)
T. arjuna bark powder at a dose of 500 mg once
daily for 30 days was compared with a known
antioxidant, vitamin E (400 units once daily)
Signiﬁcant reduction in lipids
(total cholesterol, LDL-cholesterol)
Lowering of lipid peroxide in T. arjuna group
Gupta et al88
Effect on endothelial dysfunction Asymptomatic 18 health chronic
smokers and 18 non-smokers
Double-blind, placebo-controlled, crossover
design. 500 mg aqueous extract of T. arjuna
bark powder administrated thrice daily
Improvement in brachial artery
ﬂow mediated dilation
Bharani et al89
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index (LV [dP/dt] max/LVP), and a rise in LV end-diastolic pressure.
Altered lipid proﬁle, oxidative stress, and increased levels of
endothelin 1 (ET-1), tumor necrosis factor-a (TNF-a), and inter-
leukin 6 (IL-6) along with histological changes in heart and
pancreas were observed in diabetic rats. T. arjuna signiﬁcantly
attenuated cardiac dysfunction and myocardial injury in diabetic
rats. It also reduced oxidative stress, ET-1, and inﬂammatory cyto-
kine levels.72 Sinha et al73 has investigated the antioxidative
properties of an ethanol extract of the bark of T. arjuna (TAEE)
against sodium ﬂuoride (NaF)-induced oxidative stress in the mu-
rine heart. NaF intoxication signiﬁcantly altered all the indices
related to the prooxidanteantioxidant status of the heart. In addi-
tion, the ferric reducing/antioxidant power assay revealed that
TAEE enhanced the cardiac intracellular antioxidant activity.
Finally, they concluded that TAEE protects murine hearts from NaF-
induced oxidative stress, probably via its antioxidant properties.
Parveen et al74 examined the protective effect of T. arjuna bark
extract on left ventricular (LV) and baroreﬂex function in chronic
heart failure and to elucidate the possible mechanistic clues in its
cardioprotective action. Fifteen days after isoproterenol admin-
istration, rats exhibited cardiac dysfunction, hypertrophy, and LV
remodeling along with reduced baroreﬂex sensitivity. Prophy-
lactic and therapeutic treatment with T. arjuna improved cardiac
functions and baroreﬂex sensitivity. It has also attenuated hy-
pertrophy and ﬁbrosis of the LV. T. arjuna exerts beneﬁcial effect
on LV functions, myocardial remodeling, and autonomic control
in chronic heart failure possibly through maintaining endogenous
antioxidant enzyme activities, inhibiting lipid peroxidation and
cytokine levels. Diethyl ether, ethyl acetate and ethanol extrac-
tions of T. arjuna exerted hypolipidemic and antioxidative effects
at two different dose levels of 175 and 350 mg/kg body weight in
Poloxamer (PX)-407 induced hyperlipidemic albino Wistar rats.
The results suggested that the ethanolic fraction of T. arjuna
possesses the potent properties of being an antioxidant and
hypolipidemic than other fractions.75 Kumar et al76 evaluated the
effects of T. arjuna bark extract on myocardial ﬁbrosis and
oxidative stress induced by chronic b-adrenoceptor stimulation.
Because myocardial ﬁbrosis and oxidative stress accompany a
number of cardiac disorders such as hypertrophic cardiomyopa-
thy, hypertensive heart disease and cardiac failure. Aqueous
extract of T. arjuna bark was evaluated at 63, 125 and 250 mg/kg
given orally for antiﬁbrotic and antioxidant effects in rats given
the selective b-adrenoceptor agonist isoprenaline for 28 days. The
T. arjuna bark extract signiﬁcantly prevented the isoprenaline-
induced increase in oxidative stress and decline in endogenous
antioxidant level and also prevented ﬁbrosis. Gauthaman et al79
studied that oral administration of T. arjuna for 12 weeks in
rabbits caused augmentation of myocardial antioxidants; super-
oxide dismutase (SOD), catalase (CAT) and glutathione (GSH)
along with induction of heat shock protein72 (HSP72). In vivo
ischemic-reperfusion injury induced oxidative stress, tissue
injury of heart and hemodynamic effects were prevented in the
T. arjuna treated rabbit hearts.
Alcoholic extract of T. arjuna bark and its extracts were evalu-
ated for DNA protection, protein oxidation and free radical scav-
enging activity. Ethanolic extract of T. arjuna bark (TAA) and its
fractions, including dichloromethane (TAD), ethyl acetate (TAE),
butanol (TAB) and water (TAW) has signiﬁcant antioxidant activity
and potential to prevent protein oxidation, DNA damage protection
by pBR 322 DNA and SCGE assay. The potent antioxidative activity
and DNA protection ability of T. arjuna bark extracts might be
endorsed with phenolic/ﬂavonoid compounds. A signiﬁcant cor-
relationwas also observed between free radical scavenging activity,
in vitro DNA damage activity and the total phenolic/ﬂavonoidcontent.16 Physicochemical property and inotropic effect of the
aqueous extract of T. arjuna bark (TAAqE) were investigated by
Oberoi et al80 on adult rat ventricular myocytes in comparisonwith
extracts prepared sequentially with organic extracts. They found
that TAAqE decoctions exerted positive inotropy, accelerated
myocyte relaxation and increased caffeine-induced contraction
concentration dependently. TAAqE-induced cardiotonic action via
enhancing SR function, a unique action minimizing the occurrence
of arrhythmias, makes TAAqE a promising and relatively safe
cardiotonic beneﬁcial to the healthy heart and the treatment for
chronic heart disease.
Mandal et al77 investigated antioxidative and antimicrobial
properties of methanolic extract of T. arjuna bark. The antimicrobial
activity showed that higher inhibition against Gram negative bac-
teria than gram positive bacteria and showed a promising antiox-
idant activity, as absorption of DPPH radicals decreased in DPPH
free radical scavenging assay. Methanol extract from bark of
T. arjuna exhibited medicinal as well as physiological activities.
Methanol, ethanol, acetone, aqueous both hot and cold extracts
from the leaves and bark of T. arjuna were tested for their antimi-
crobial activity against Staphylococcus aureus, Acinetobacter sp.,
Proteus mirabilis, Escherichia coli, Pseudomonas aeruginosa and
Candida albicans, pathogens causing ear infections. Three organic
solvents evaluated, acetonic leaf extract was found to be best
against S. aureus. Organic bark extract showed almost equal inhi-
bition of all tested Gram negative bacteria except P. aeruginosa.
Aqueous extract of T. arjuna bark exhibited good activity against
S. aureus.78 Devi et al81 evaluated the effect of methanolic extract of
T. arjuna (100 mg/kg to 50 mg/kg body weight) on diclofenac so-
dium (80 mg/kg bodyweight in water, orally) induced gastric ulcer
in rats. The gastroprotective effect of T. arjuna was assessed from
volume of gastric juice, pH, free and total acidity, pepsin concen-
tration, acid output in gastric juice, the levels of non-protein sulf-
hydryls (NP-SH), lipid peroxide (LPO), reduced glutathione (GSH),
and activities of enzymic antioxidants-super oxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-
transferase (GST) and myeloperoxidase (MPO) in gastric mucosa.
The levels of DNA, protein bound carbohydrate complexes-hexose,
hexosamine, sialic acid, fucose in gastric mucosa and gastric juice
and the levels of RNA in gastric mucosawere assessed. The stomach
tissues were used for adherent mucus content and also for the
histological examination. A signiﬁcant reduction in lesion index
was observed in ulcer induced animals treated with T. arjuna
(DIC þ TA) compared to ulcerated rats (DIC). A signiﬁcant increase
was observed at pH, NP-SH, GSH, enzymic antioxidants, protein
bound carbohydrate complexes, adherent mucus content, nucleic
acids with a signiﬁcant decrease in volume of gastric juice, free and
total acidity, pepsin concentration, acid output, LPO levels andMPO
activities in DIC þ TA rats compared to DIC rats. It is proved that
T. arjuna could act as a gastroprotective agent probably due to its
free radical scavenging activity and cytoprotective nature.
5.2. Clinical studies
Recently, Kapoor et al19 investigated the therapeutic potential of
T. arjuna on the inﬂammatory markers in subjects with stable
coronary artery disease (CAD). In a placebo-controlled, randomized
double-blind study, 116 patients with stable CAD who were on
standard cardiac medications for more than three months were
enrolled and received either placebo or 500 mg of T. arjuna from
Himalayan Herbal Healthcare, Bangalore, India twice a day in
addition to receiving the conventional treatment. A signiﬁcant
decrease in serum triglycerides as well as in various inﬂammatory
cytokines such as hsCRP, IL-18 (P < 0.001), IL-6 and TNF-a (P < 0.05)
was observed at 3 months in patients who were on drug treatment
A. Amalraj, S. Gopi / Journal of Traditional and Complementary Medicine 7 (2017) 65e7876as compared to the placebo. The effects were maintained till 6
months follow-up and showed a further reduction in hyperlipid-
emia and inﬂammatory markers with time. An observational study
was conducted to ﬁnd out the effects of T. arjuna in patients with
dilated cardiomyopathy (DCMP) of idiopathic and ischemic cause.
Ninety three patients with DCMP receiving standard therapy and/
or bark extract of T. arjuna 500 mg 8 hourly were enrolled. Three
groups as standard therapy (ST, Group 1), T. arjuna therapy (TA,
Group 2) and standard therapy with T. arjuna (ST þ TA, Group 3)
were formed. At the end of the study period, patients of group 3
showed signiﬁcant improvement in percentage of left ventricular
ejection fraction (LVEF%) (7 ± 1.6, P < 0.00001) compared to group 1
and 2 (P < 0.00001, P < 0.0001). Reductions in Left ventricular end
systolic and diastolic diameters and volumes were most signiﬁcant
in group 3 (8.3 ± 4.7, P < 0.0001 and 3.1 ± 5.7, P < 0.001) and
(11 ± 26, 9 ± 21 P < 0.01) respectively in comparison to other
groups. Pulmonary artery pressure reduced signiﬁcantly in group 1
and 3 (P < 0.0001). A similar reduction in diastolic score and mitral
regurgitation (P < 0.01 and P < 0.0001) was observed in groups 1
and 3. From the results, dilated cardiomyopathy with reduced LVEF
due to either idiopathic or ischemic cause receiving standard
therapy with T. arjuna showed signiﬁcant improvement in left
ventricular parameters as well as functional capacity.82
Bharani et al83 investigated the salutary effect of T. arjuna in
patients with severe refractory heart failure. Twelve patients with
refractory chronic congestive heart failure (Class IV NYHA), related
to idiopathic dilated cardiomyopathy (10 patients); previous
myocardial infarction (one patient) and peripartum cardiomyopathy
(one patient), received T. arjuna, as bark extract (500mg 8 hourly) or
matching placebo for 2 weeks each, separated by 2 week washout
period, in a double blind crossover design as an adjuvant to maxi-
mally tolerable conventional therapy (Phase I). On long term eval-
uation in an open design (Phase II), wherein Phase I participants
continued T. arjuna in ﬁxed dosage (500 mg 8-hourly) in addition to
ﬂexible diuretic, vasodilator and digitalis dosage for 20e28 months
(mean 24 months) on outpatient basis, patients showed continued
improvement in symptoms, signs, effort tolerance and NYHA Class,
with improvement in quality of life. Dwivedi et al84 were conducted
a study to evaluate the role of T. arjuna in ischemic mitral regurgi-
tation (IMR) following acute myocardial infarction (AMI). 40 pa-
tients with fresh AMI showing IMR were randomly divided into 2
groups of 20 each. Two groups were observed between one and
three months therapy with T. arjuna at a dose of 500 mg twice a day
and showed signiﬁcant decreases in IMR, improvement in E/A ratio
and considerable reduction in angina frequency. Bharani et al85
conducted a study on the efﬁcacy of T. arjuna in chronic stable
angina. Fifty eight males with chronic stable angina (NYHA class
IIeIII) with evidence of provocable ischemia on treadmill exercise
test received TA (500 mg 8 hourly), isosorbide (40 mg/daily) or a
matching placebo for one week each, separated by awashout period
of at least three days in a randomized, double-blind, crossover
design. They underwent clinical, biochemical and treadmill exercise
evaluation at the end of each therapy, which were compared during
the three therapy periods. T. arjuna therapy was associated with a
signiﬁcant decrease in the frequency of angina and the need for
isosorbide dinitrate. T. arjuna bark extract, 500 mg 8 hourly, given to
patients with stable angina with provocable ischemia on treadmill
exercise, led to improvement in clinical and treadmill exercise pa-
rameters as compared to placebo therapy. These beneﬁts were
similar to those observed with isosorbide mononitrate (40 mg/day)
therapy and the extract was well tolerated.
The effect of an Ayurvedic formulation of T. arjuna, known as
‘Arjuna Kwatha’ was assessed by Rao et al86 in 36 hypertensive
patients at stage III with increased LV mass. The patients were
divided into two groups, one group received atenolol (50 mg twicedaily) and the other group ‘Arjuna Kwatha’ (25 ml twice daily) along
with atenolol for 6 months. A signiﬁcant decrease was observed in
both SBP and DBP (P < 0.001) in both the groups. However, LV mass
index was only signiﬁcantly reduced in the atenolol-plus-‘Arjuna
Kwatha’ group as compared to atenolol alone (P < 0.001), due to
negative chronotropic and inotropic effects of the herbal prepara-
tion. Khalil87 reported that the administration of T. arjuna bark
powder alongwith statins for 3months to 30 patients with coronary
artery disease resulted in a 16% in LDL-cholesterol, 15% decrease in
total cholesterol and 11% in triglycerides, conﬁrming its immense
potential to correct dyslipidemia in conjunction with statins. Gupta
et al88 evaluated the antioxidant and hypocholesterolaemic effects
of T. arjuna tree bark and to compare it with a known antioxidant,
vitamin E, also performed a randomized controlled trial. One hun-
dred and ﬁve successive patients with coronary heart disease (CHD)
were recruited and divided into 3 groups of 35 each in this study.
Group I received placebo capsules; Group II vitamin E capsules 400
units/day; and Group III received ﬁnely pulverized T. arjuna tree
bark-powder (500 mg) in capsules daily. Lipids and lipid peroxide
levels were determined at 30 days follow-up. No signiﬁcant changes
in total, HDL, LDL cholesterol and triglycerides levels were seen in
Groups I and II. In Group III, there was a signiﬁcant decrease in total
cholesterol (9.7 ± 12.7%), and LDL cholesterol (15.8 ± 25.6%)
(paired t-test P < 0.01). Lipid peroxide levels decreased signiﬁcantly
in both the treatment groups (P < 0.01). This decrease was more in
vitamin E group (36.4 ± 17.7%) as compared to the T. arjuna group
(29.3 ± 18.9%). T. arjuna tree bark powder has signiﬁcant antioxi-
dant action that is comparable to vitamin E and also has a signiﬁcant
hypocholesterolaemic effect. A study was conducted by Bharani
et al89 to determine the improvement of endothelial dysfunction in
smokers. Eighteen healthy male smokers (age 28.16 ± 9.45 years)
and an equal number of age-matched, non-smoker controls partic-
ipated in the study. The smokers were given T. arjuna (500 mg, 8 h)
ormatching placebo randomly in a double blind crossover design for
two weeks each, followed by repetition of brachial artery reactivity
studies to determine various parameters including ﬂow-mediated
dilation after each period. The ﬂow-mediated dilation showed sig-
niﬁcant improvement from baseline values after T. arjuna therapy.
6. Toxicity and side effects
T. arjuna has been used in the dose between 1 to 2 g per day in
different clinical studies and found that this is an optimum dose in
the patients particularly CAD. These doses have lesser side effect
like headache, mild gastritis and constipation. There were no re-
ports in the regards of hematological, hepatic, metabolic and renal
toxicity after more than two years of its administration.83 Recently
Bhawani et al82 reported that there was no signiﬁcant variation in
the body and organ weights between the control and the treated
group of 93 patients with dilated cardiomyopathy (DCMP) of idio-
pathic and ischemic cause was observed after 28 days of treatment
under the treatment of T. arjuna capsules (500 mg at 8 h). Hema-
tological analysis and biochemical parameters revealed no toxic
effects of the extract. Pathologically, neither gross abnormalities
nor histopathological changes were observed and there was no
mortality recorded in 28 days. Yaidikar et al90 reported that pre-
treatment with arjunolic acid from the T. arjuna bark effectively
prevented the cerebral I/R induced oxidative damage by virtue of its
antioxidant potential and supplementation of arjunolic acid may be
beneﬁcial in stroke prone population. Arjunolic acid from T. arjuna
attenuated sodium nitrite-induced cardiac damage in rats and
restored the normal balance between pro- and anti-inﬂammatory
cytokines. Moreover, arjunolic acid protected cardiac tissues from
both extrinsic and intrinsic cell death pathways.91 Parmar et al92
were observed a decrease in serum concentration of thyroid
A. Amalraj, S. Gopi / Journal of Traditional and Complementary Medicine 7 (2017) 65e78 77hormones as well as an increase in the hepatic LPO with higher
doses of T. arjuna. There is a vital need for well controlled multi-
centric clinical trials in a larger setup of subjects with a standard-
ized product for exploring the true therapeutic potential of
T. arjuna.
7. Conclusion
On the basis of the available literature evidences, T. arjuna is
widely used for treatment of cardiovascular diseases, including
heart diseases and related chest pain, high blood pressure and high
cholesterol. It is also used for earaches and diseases of the urinary
tract. The effectiveness T. arjuna as an anti-ischemic agent and as a
potent antioxidant preventing LDL, reperfusion ischemic injury to
the heart and its potential to reduce atherogenic lipid levels have
been sufﬁciently demonstrated in different experimental and
clinical studies. However, continuous research progress of using
T. arjuna is very much needed in the regards of exact molecular
mechanism, drug administration, drug-drug interactions and
toxicological studies.
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